81 related articles for article (PubMed ID: 35072084)
1. Angiotensin II for the Treatment of Refractory Shock: A Matched Analysis.
Smith LM; Mentz GB; Engoren MC
Crit Care Med; 2023 Dec; 51(12):1674-1684. PubMed ID: 37378469
[TBL] [Abstract][Full Text] [Related]
2. Vasopressor hormones in shock-noradrenaline, vasopressin or angiotensin II: which one will make the race?
Dünser MW; Meier J
J Thorac Dis; 2017 Jul; 9(7):1843-1847. PubMed ID: 28839980
[No Abstract] [Full Text] [Related]
3. Costs and Resources Must Impact Clinical Decision-Making in the ICU: The Case of Vasopressor Use.
Bauer SR; Devlin JW
Crit Care Med; 2024 Jul; ():. PubMed ID: 38949473
[No Abstract] [Full Text] [Related]
4. Vasopressor use and pressure injury risk. Only in the eye of the beholder?
Mellinghoff J; Lin F; Blot S
Intensive Crit Care Nurs; 2024 Aug; 83():103702. PubMed ID: 38636294
[No Abstract] [Full Text] [Related]
5. A double-blind randomised feasibility trial of angiotensin-2 in cardiac surgery
Coulson TG; Miles LF; Serpa Neto A; Pilcher D; Weinberg L; Landoni G; Zarbock A; Bellomo R
Anaesthesia; 2022 Sep; 77(9):999-1009. PubMed ID: 35915923
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin ii therapy in refractory septic shock: which patient can benefit most? A narrative review.
Coloretti I; Genovese A; Teixeira JP; Cherian A; Ferrer R; Landoni G; Leone M; Girardis M; Nielsen ND
J Anesth Analg Crit Care; 2024 Feb; 4(1):13. PubMed ID: 38383521
[TBL] [Abstract][Full Text] [Related]
7. Intravenous infusion of angiotensin II for treatment of cardiopulmonary bypass-induced vasoplegic shock after implantation of left ventricular assist device: a case report.
Šribar A; Mikecin V; Presečki I; Barić D; Marijančević D; Peršec J
Croat Med J; 2023 Jun; 64(3):201-204. PubMed ID: 37391918
[TBL] [Abstract][Full Text] [Related]
8. Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial.
Wieruszewski PM; Bellomo R; Busse LW; Ham KR; Zarbock A; Khanna AK; Deane AM; Ostermann M; Wunderink RG; Boldt DW; Kroll S; Greenfeld CR; Hodges T; Chow JH;
Crit Care; 2023 May; 27(1):175. PubMed ID: 37147690
[TBL] [Abstract][Full Text] [Related]
9. How Effective is Angiotensin II in Decreasing Mortality of Vasodilatory Shock? A Systematic Review.
Semedi BP; Rehatta NM; Soetjipto S; Nugraha J; Mahyuddin MH; Arnindita JN; Wairooy NAP
Open Access Emerg Med; 2023; 15():1-11. PubMed ID: 36636460
[TBL] [Abstract][Full Text] [Related]
10. A Retrospective Review of Angiotensin II Use in Adult Patients With Refractory Distributive Shock.
Wong A; Alkazemi A; Eche IM; Petri CR; Sarge T; Cocchi MN
J Intensive Care Med; 2020 Dec; 35(12):1490-1496. PubMed ID: 31480886
[TBL] [Abstract][Full Text] [Related]
11. Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study.
Chawla LS; Busse L; Brasha-Mitchell E; Davison D; Honiq J; Alotaibi Z; Seneff MG
Crit Care; 2014 Oct; 18(5):534. PubMed ID: 25286986
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II: A New Vasopressor for the Treatment of Distributive Shock.
Allen JM; Gilbert BW
Clin Ther; 2019 Dec; 41(12):2594-2610. PubMed ID: 31668356
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin II in the treatment of distributive shock: a systematic-review and meta-analysis.
Xourgia E; Exadaktylos AK; Chalkias A; Ziaka M
Shock; 2024 Jun; ():. PubMed ID: 38888542
[TBL] [Abstract][Full Text] [Related]
14. Vasopressin versus norepinephrine as the first-line vasopressor in septic shock: A systematic review and meta-analysis.
Sedhai YR; Shrestha DB; Budhathoki P; Memon W; Acharya R; Gaire S; Pokharel N; Maharjan S; Jasaraj R; Sodhi A; Kadariya D; Asija A; Kashiouris MG
J Clin Transl Res; 2022 Jun; 8(3):185-199. PubMed ID: 35813900
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of Angiotensin II for Catecholamine Refractory Septic or Distributive Shock on Mortality: A Propensity Score Weighted Analysis of Real-World Experience in the Medical ICU.
Quan M; Cho N; Bushell T; Mak J; Nguyen N; Litwak J; Rockwood N; Nguyen HB
Crit Care Explor; 2022 Jan; 4(1):e0623. PubMed ID: 35072084
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
